Press Release
UPDATED CLINICAL DATA FROM THE ADVANCE II TRIAL DEMONSTRATE THE POTENTIAL OF VIDIDENCEL TO INDUCE EFFECTIVE T CELL RESPONSES AND IMPROVE OVERALL IMMUNE STATUS IN ACUTE MYELOID LEUKEMIA
The updated clinical data to be presented are based on immunological analyses of patient samples collected as part of the ongoing ADVANCE II clinical trial in AML. The immunomonitoring data demonstrate the potential of vididencel to induce tumor antigen-specific T cell responses and improve the immune competency in patients suffering from AML. As a whole cell-based vaccine, vididencel carries a broad range of known and unknown cancer antigens. Following vididencel treatment, T cell responses against one or more tumor antigens that are regularly upregulated in AML, including WT-1, RHAMM and PRAME, were detected in the vast majority of patients (85%).
Immune profiling of peripheral blood mononuclear cells (PBMC) was done before and during vididencel treatment to evaluate changes in immune cell composition. Clear differences were observed at baseline between patients who experienced durable clinical remissions and patients who relapsed. An immune compromised profile characterized by high levels of CD8+ central memory (CM) T cells and CD8+ LAG3+ suppressor T cells, combined with low levels of B-cells and dendritic cells (cDC1 and cDC2) was observed in relapsed patients, as compared to patients who experienced clinical benefit. During vididencel treatment, changes in immune cell composition were observed towards a more immune competent profile, shown by increases in dendritic cells, B-cells and decreases in CD8+ LAG3+ cells. Heatmap analysis per patient showed clear shifts in immune cell compositions over time.
The data support vididencel’s mechanism of action as a therapy that improves immune control over residual disease, resulting in prolonged disease-free survival. The results also provide for a deeper understanding on the role of the individual immune cell subsets in the mounting of an effective anti-tumor immune response. Vididencel treatment resulted in an overall improvement of the immune status towards an immune competent profile and high numbers of T-cell responses, associated with longer relapse-free and overall survival.
Please see below for abstract details:
Abstract Number: 151 (poster presentation)
Abstract Title: Vaccination with a leukemic-cell derived cancer vaccine (vididencel) improves anti-tumor immune competency in AML patients correlating with improved survival
Authors:
Session Date & Time: Thursday,
Please see below for abstract details:
Abstract Number: 57 (poster presentation)
Abstract Title: DCOne-derived dendritic cells promote robust in vitro expansion of memory NK cells with strong tumor cell cytotoxicity and high persistence
Authors: Haoxiao Zuo,
Session Date & Time: Wednesday,
The abstracts are available on the CIMT 2024 conference website. After the conference, the posters will be available on the
© Modular Finance, source